Anti-CD95L monoclonal neutralizing antibody
Anti-CD95L monoclonal antibodies like JQ3 address the issue of CD95L-mediated inflammation and cancer cell survival by neutralizing CD95L, effectively reducing inflammation and inhibiting cancer cell survival in chronic inflammatory diseases and cancers.
Patent Information
- Application Number
- JP2024533122
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-12-01
- Filing Date
- 2022-11-30
- Publication Date
- 2024-11-27
AI Technical Summary
Current treatments for chronic inflammatory diseases and cancers are inadequate in addressing the exacerbation of inflammation and survival of cancer cells due to CD95L-mediated non-apoptotic signaling pathways, particularly through soluble CD95L (s-CD95L), which induces inflammation and promotes chemoresistance.
Development of anti-CD95L monoclonal neutralizing antibodies, such as JQ3, that specifically target and neutralize CD95L, inhibiting non-apoptotic signaling pathways and reducing inflammation and cancer cell survival.
The anti-CD95L monoclonal antibodies effectively block CD95-mediated calcium responses in neutrophils, reducing inflammation and inhibiting cancer cell survival, as demonstrated in various inflammatory diseases and cancers, including COVID-19 and ANCA-associated vasculitis.
Smart Images

Figure 2024544076000001 
Figure 2024544076000002 
Figure 2024544076000003
Abstract
Description
[Technical field]
[0001] The present invention is in the fields of immunology and oncology. [Background technology]
[0002] Chronic inflammatory diseases have become a major cause of death worldwide. Although such diseases appear clinically distinct, they share many similarities in genetic background and pathophysiological pathways. Accumulating evidence suggests that the trafficking of IL-17-producing CD4+ effector T cells, termed Th17 cells, and their subsequent accumulation in organs induces the inflammation and tissue lesions that are responsible for the clinical symptoms associated with such diseases.
[0003] CD95L (FasL) belongs to the tumor necrosis factor (TNF) family and is the ligand for the death receptor CD95 (also known as Fas). Whereas CD95 is widely expressed on healthy cells, CD95L shows a restricted expression pattern, mainly detected on the surface of lymphocytes, where it plays a central role in the elimination of infected and transformed cells (Strasser, A.; Jost, PJ; Nagata, S. The many roles of FAS receptor signaling in the immune system. Immunity. 2009, 30, 180-192). CD95L is a transmembrane glycoprotein that acts locally through cell-cell contacts, and after cleavage by metalloproteases, soluble CD95L (s-CD95L) is released into the bloodstream. This soluble ligand contributes to exacerbation of inflammation in chronic inflammatory diseases such as systemic lupus erythematosus (SLE) by inducing non-apoptotic signaling pathways such as NF-κB and PI3K (Tauzin, S. et al. PLoS Biol. 2011, 9, e1001090), and may exert pro-oncogenic functions by promoting survival in ovarian and liver cancer, and chemoresistance in lung cancer. The CD95L receptor, called CD95 or Fas, has an intracellular conserved portion, the death domain (DD), which acts as a docking platform to induce cell death. Binding of the membrane-bound hexameric CD95L to CD95 leads to recruitment of the adaptor protein FADD (Fas-associated death domain) through homotypic interaction via their respective DDs (Holler, N. et al., Mol Cell Biol. 2003, 23, 1428-1440). FADD then aggregates the initiators caspase-8 and caspase-10. The CD95 / FADD / caspase complex is called the death-inducing signaling complex (DISC) and leads to the elimination of cancer cells by an apoptotic mechanism (Kischkel, FC et al. Embo J. 1995, 14, 5579-5588). In contrast, homotrimeric s-CD95L does not induce DISC formation but instead mediates the Ca 2+It induces the formation of a non-apoptotic complex called the motility-inducing signaling complex (MISC) that responds to s-CD95L (Tauzin, S. et al. PLoS Biol. 2011, 9, e1001090). Recent data have revealed that s-CD95L induces calcium responses by inducing a direct interaction between CD95 and PLCγ1 (Poissonnier, A. et al. Immunity. 2016, 45, 209-223). Indeed, in the presence of s-CD95L, the juxtamembrane region of CD95, called the calcium induction domain (CID), recruits PLCγ1 to induce endothelial transmigration of Th17 cells in SLE (Poissonnier, A. et al. Immunity. 2016, 45, 209-223).
[0004] Therefore, there is interest in developing agents that inhibit CD95-mediated non-apoptotic signaling pathways that contribute to inflammation. In particular, there is a high demand for neutralizing anti-CD95L monoclonal antibodies.
[0005] US Pat. No. 5,399,433 discloses several anti-CD95L monoclonal neutralizing antibodies, and in particular the NOK1 antibody. [Prior art documents] [Patent documents]
[0006] [Patent Document 1] International Publication No. 1996 / 029350 Summary of the Invention [Means for solving the problem]
[0007] The invention is defined by the claims. In particular, the invention relates to anti-CD95L monoclonal neutralizing antibodies and their use for therapeutic purposes. [Brief description of the drawings]
[0008] [Figure 1]Figure 1 shows that JQ3 recognizes human and monkey CD95L and is a potent anti-CD95L neutralizing mAb compared to the commercial anti-CD95L antibody NOK-1. A shows the Kon, Koff, and Kd of JQ3 (IgG1κ) and NOK-1 (IgG1κ) hybridomas measured by surface plasmon resonance. IgCD95L was immobilized on a Sensor Chip S CM5 and antibody binding properties were evaluated using a Biacore T200. B shows the ability of anti-human CD95L monoclonal antibodies NOK-1 and JQ3 and anti-mouse CD95L monoclonal antibody MFL3 (1 μg / ml) to recognize human, monkey, or mouse CD95L was determined by flow cytometry using HEK / 293T cells transiently transfected with pcDNA3.1 vectors encoding the indicated CD95L. C shows that the binding efficiency of NOK-1 and JQ3 was compared by flow cytometry to the CD95L-expressing 1A12 cell line. The left panel reports the intensity of CD95L staining (mean CD95L fluorescence - mean isotype fluorescence) as a function of antibody concentration (M) by a histogram. The right panel shows examples of CD95L staining, with JQ3 or NOK-1 staining in red and isotype staining in grey. The table shows the half maximal effective concentration (EC50) of each antibody. D shows that the neutralizing capacity of NOK1 and JQ3 mAbs was compared by incubating a CD95-sensitive Jurkat cell line (5.105 cells) with 100 ng / mL Ig-CD95L (soluble and cytotoxic human CD95L) for 24 h in the presence or absence of the indicated concentrations of antibodies. [Diagram 2]Figure 2 shows that NOK-1 and JQ3 mAbs together with the CD95 inhibitor DB550 inhibit neutrophil activation (calcium response) by AAV or COVID-19 patient serum. Healthy donor (HD) neutrophils were loaded with calcium (Ca2+) probe cal-520. Fluorescence values (F) were normalized to pre-stimulation values (F0) to obtain F / F0 values (relative [Ca2+]cyt). Data represent mean ± sd [Ca2+]cyt (cytoplasmic Ca2+ concentration). A shows that neutrophils were preincubated with or without DB550 (1 μM) (control) for 30 min and then exposed to the indicated serum. Meanwhile, COVID-19 patient serum was preincubated in the presence of NOK-1 or JQ3 (10 μg / mL) for 30 min, after which neutrophils were stimulated with the indicated serum and intracellular calcium concentration was monitored. B shows that HD neutrophils were preincubated with or without DB550 (1 μM) (control) for 30 min and then exposed to the serum presented. Meanwhile, antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) patient serum was preincubated with or without NOK-1 or JQ3 (10 μg / mL) for 30 min. HD neutrophils were then exposed to the serum presented and intracellular calcium concentration was monitored. C shows that DMSO treatment induces differentiation of bone marrow HL60 cell line into neutrophils. DMSO-treated HL60 cells were preincubated with or without DB550 (1 μM) (control) for 30 min. Meanwhile, serum from healthy donor (HD3), AAV (AAV45), and COVID-19 (Covid15) patient serum was preincubated with or without NOK-1 or JQ3 (10 μg / mL) for 30 min. DMSO-treated HL60 cells were then stimulated with the indicated sera and intracellular calcium concentrations were monitored. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0009] Key Definitions As used herein, the terms "polypeptide", "peptide" and "protein" are used interchangeably herein to refer to any length of amino acid polymer.The terms also include modified amino acid polymers, such as disulfide bond formation, glycosylation, lipidation, phosphorylation, or conjugation with labeling components.When describing in the context of gene therapy, polypeptide refers to each intact polypeptide, or any fragment or genetically engineered derivative thereof that retains the desired biochemical function of intact protein.
[0010] As used herein, the term "polynucleotide" refers to a polymeric form of nucleotides of any length, including deoxyribonucleotides or ribonucleotides, or analogs thereof. Polynucleotides can include modified nucleotides, such as methylated nucleotides, and nucleotide analogs, and can be interrupted by non-nucleotide components. Modifications of nucleotide structure, if present, can be made before or after the formation of the polymer. The term polynucleotide, as used herein, refers interchangeably to double-stranded and single-stranded molecules. Unless otherwise specified or required, any embodiment of the invention described herein that is a polynucleotide encompasses both the double-stranded form and each of the two complementary single-stranded forms that are known or predicted to constitute the double-stranded form.
[0011] As used herein, the term "derived from" refers to a process in which a first component (e.g., a first polypeptide) or information about a first component is used to isolate, derive, or create a different, second component (e.g., a second polypeptide that is different from the first polypeptide).
[0012] As used herein, the "percent identity" between two sequences is a function of the number of identical positions shared by the sequences (i.e., % identity = number of identical positions / total number of positions x 100), taking into account the number of gaps and the length of each gap that need to be introduced for optimal alignment of the two sequences. Sequence comparison and determination of percent identity between two sequences can be performed using a mathematical algorithm, as described below. Percent identity between two amino acid sequences can be determined using the Needleman-Wunsch algorithm (Needleman, Saul B. & Wunsch, Christian D. (1970). "A general method applicable to the search for similarities in the amino acid sequence of two proteins". Journal of Molecular Biology. 48(3): 443-53.). Percent identity between two nucleotide or amino acid sequences can also be determined using algorithms such as, for example, EMBOSS Needle (pairwise alignment, available at www.ebi.ac.uk). For example, EMBOSS Needle can be used with the BLOSUM62 matrix, a "gap open penalty" of 10, a "gap extension penalty" of 0.5, a false "end gap penalty", an "end cap open penalty" of 10, and an "end gap extension penalty" of 0.5. In general, the "percent identity" is a function of the number of matching positions divided by the number of positions compared, multiplied by 100. For example, if after alignment 6 out of 10 sequence positions are identical between the two compared sequences, the identity is 60%. The percent identity is typically determined over the entire length of the query sequence that is being analyzed. Two molecules that have the same primary amino acid or nucleic acid sequence are identical, regardless of any chemical and / or biological modifications.In the present invention, a first amino acid sequence having at least 70% identity to a second amino acid sequence means that the first sequence has 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% identity to the second amino acid sequence.
[0013] As used herein, the term "encode" refers to the unique property of a particular sequence of nucleotides in a polynucleotide, e.g., a gene, cDNA, or mRNA, to serve as a template for the synthesis of other polymers and macromolecules in biological processes that have either a defined nucleotide sequence (e.g., rRNA, tRNA, and mRNA) or a defined amino acid sequence and the biological properties derived therefrom. Thus, a gene, cDNA, or RNA encodes a protein when it produces a protein in a cell or other biological system by transcription and translation of the mRNA corresponding to that gene. Both the coding strand, whose nucleotide sequence is identical to the mRNA sequence and is usually shown in the sequence listing, and the non-coding strand used as a template for transcription of the gene or cDNA, can be referred to as encoding a protein or other product of the gene or cDNA. Unless specified, a "nucleotide sequence encoding an amino acid sequence" includes all nucleotide sequences that are degenerate versions of each other and that encode the same amino acid sequence. Also, the phrase "nucleotide sequence or RNA encoding a protein" can include introns to the extent that a nucleotide sequence encoding a protein may include introns in some types.
[0014] As used herein, the term "CD95L" has its general meaning in the art and refers to the cognate ligand of the transmembrane protein CD95. This term is also known as APT1LG1, FASL, and TNFSF6. An exemplary amino acid sequence of CD95L is shown in SEQ ID NO:1. The extracellular domain of human CD95L typically consists of the amino acid sequence ranging from amino acid residue 103 to amino acid residue 281 in SEQ ID NO:1. SEQ ID NO:1 >sp|P48023|TNFL6_HUMAN Tumor necrosis factor ligand superfamily member 6 OS=Homo sapiens OX=9606 GN=FASLG PE=1 SV=1. The extracellular domain is underlined in the sequence. MQQPFNYPYPQIYWVDSSASSPWAPPGTVLPCPTSVPRRPGQRRPPPPPPPPPLPPPPPPPPLPPLPLPPLKKRGNHSTGLCLLVMFFMVLVALVGLGLGMF QLFHLQKELAELRESTSQMHTASSLEKQIGHPSPPPEKKELRKVAHLTGKSNSRSMPLEWEDTYGIVLLSGVKYKKGGLVINETGLYFVYSKVYFRGQSCNNLPLSHKVYMRNSKYPQDLVMMEGKMMSYCTTGQMWARSSYLGAVFNLTSADHLYVNVSELSLVNFEESQTFFGLYKL
[0015] As used herein, the term "soluble CD95L" has its general meaning in the art and refers to the soluble ligand produced by cleavage of transmembrane CD95L by a metalloprotease. The terms "serum CD95L", "soluble CD95L", "metalloprotease-cleaved CD95L", and "s-CD95L" have the same meaning herein.
[0016] As used herein, the terms "antibody" and "immunoglobulin" have the same meaning and can be used equally in the present invention. The term "antibody" as used herein refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antigen-binding site that immunospecifically binds an antigen. Thus, the term antibody includes not only whole antibody molecules, but also antibody fragments and variants (including derivatives) of antibodies and antibody fragments. In natural antibodies, two heavy chains are linked to each other by disulfide bonds, and each heavy chain is linked to one light chain by a disulfide bond. There are two types of light chains: lambda (1) and kappa (k). There are five main heavy chain classes (or isotypes), IgM, IgD, IgG, IgA, and IgE, which determine the functional activity of antibody molecules. Each chain contains a specific sequence domain. The light chain contains two domains: a variable domain (VL) and a constant domain (CL). Heavy chains contain three (α, δ, γ) to five (μ, ε) domains: a variable domain (VH) and three to four constant domains (CH1, CH2, CH3, and CH4, collectively referred to as CH). The variable regions of both the light chain (VL) and the heavy chain (VH) determine the binding recognition and specificity to the antigen. The constant region domains of the light chain (CL) and the heavy chain (CH) confer important biological properties such as antibody chain association, secretion, transplacental transfer, complement binding, and binding to Fc receptors (FcR). The Fv fragment is the N-terminal part of the Fab fragment of an immunoglobulin and consists of the variable portions of one light chain and one heavy chain. The specificity of an antibody resides in the structural complementarity between the antibody binding site and the antigenic determinant. The antibody binding site is mainly composed of residues from the hypervariable regions or complementarity determining regions (CDRs). Occasionally, residues from non-hypervariable or framework regions (FR) may participate in the antibody binding site or may influence the overall domain structure, i.e., the combining site. CDRs refer to amino acid sequences which together define the binding affinity and specificity of the natural Fv region of a native immunoglobulin binding site.The light and heavy chains of immunoglobulins each have three CDRs, called L-CDR1, L-CDR2, L-CDR3, and H-CDR1, H-CDR2, H-CDR3. Thus, an antigen-binding site typically comprises six CDRs, including a set of CDRs from each of the heavy and light chain V regions. Framework region (FR) refers to the amino acid sequence located between the CDRs. In the present invention, the amino acid residues in the variable domain, complementarity determining region (CDR) and framework region (FR) of the antibody of the present invention are identified using the Immunogenetics (IMGT) database (http: / / imgt.cines.fr) (Lefranc et al. (2003) Dev Comp Immunol. 27(1):55-77). The IMGT database was developed using sequence information from immunoglobulin (IgG), T-cell receptor (TcR), and major histocompatibility complex (MHC) molecules, with uniform numbering across antibody lambda and kappa light chains, heavy chains, and T-cell receptor chains, and no insertion codes except for rare length insertions. IMGT also takes into account and combines the definition of framework regions (FR) and complementarity determining regions (CDR) by Kabat et al., the characterization of hypervariable loops by Chothia et al., and structural data from X-ray diffraction studies.
[0017] As used herein, the terms "monoclonal antibody," "monoclonal Ab," "monoclonal antibody composition," "mAb," and the like, as used herein, refer to a preparation of antibody molecules of single molecular composition. Monoclonal antibodies are obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations which may be present in minor amounts.
[0018] As used herein, the term "chimeric antibody" refers to an antibody that comprises the VH and VL domains of a non-human antibody and the CH and CL domains of a human antibody.
[0019] As used herein, the term "humanized antibody" refers to an antibody that has variable, framework, and constant regions from a human antibody, but retains the CDRs of a previous non-human antibody. In some embodiments, a humanized antibody contains minimal non-human immunoglobulin-derived sequences. In many cases, humanized antibodies and antibody fragments thereof may be human immunoglobulins (recipient antibodies or antibody fragments) in which the residues of the recipient complementarity determining regions (CDRs) are replaced with the residues of the CDRs of a non-human species (donor antibody) such as mouse, rat, or rabbit that has the desired specificity, affinity, and capacity.
[0020] As used herein, the term "antibody fragment" refers to at least a portion of an intact antibody, preferably the antigen-binding or variable region of the intact antibody, that retains the ability to specifically interact with an epitope of an antigen (e.g., by binding, steric hindrance, stabilization / destabilization, spatial distribution). A "fragment" includes a portion of an intact antibody, generally the antigen-binding site or variable region. Examples of antibody fragments include Fab, Fab', Fab'-SH, F(ab')2, and Fv fragments, diabodies, any antibody fragment that is a polypeptide having a primary structure consisting of an uninterrupted sequence of contiguous amino acid residues (herein referred to as "single-chain antibody fragment" or "single-chain polypeptide"), including, without limitation, (1) a single-chain Fv molecule, (2) a single-chain polypeptide comprising only one light chain variable domain without associated heavy chain portions, or a fragment thereof comprising the three CDRs of the light chain variable domain, and (3) a single-chain polypeptide comprising only one heavy chain variable region without associated light chain portions, or a fragment thereof comprising the three CDRs of the heavy chain variable region, as well as multispecific antibodies formed from antibody fragments. Fragments of the antibodies can be obtained using standard methods.
[0021] As used herein, "Fc region" has its general meaning in the art and includes the polypeptide that includes the constant region of an antibody other than the first constant region immunoglobulin domain. Thus, Fc refers to the last two constant region immunoglobulin domains of IgA, IgD, and IgG, and the last three constant region immunoglobulin domains of IgE and IgM, and the N-terminal movable hinges of these domains. In IgA and IgM, Fc can include the J chain. In IgG, Fc includes the immunoglobulin domains Cgamma2 and Cgamma3 (Cγ2 and Cγ3), and the hinge between Cgamma1 (Cγ1) and Cgamma2 (Cγ2). Although the boundaries of the Fc region may vary, the Fc region of a human IgG heavy chain is usually defined to include residues C226 or P230 to its carboxyl terminus, with numbering according to the EU index as in Kabat et al. (1991, NIH Publication 91-3242, National Technical Information Service, Springfield, Va.). "EU index as described by Kabat" refers to the residue numbering of the EU antibody of human IgG1 as described by Kabat et al., supra. Fc may refer to this region in isolation or to this region in the case of an antibody, antibody fragment, or Fc fusion protein. An Fc variant protein can be an antibody, an Fc fusion, or any protein or protein domain that includes an Fc region. Particularly preferred are proteins that include variant Fc regions that are non-naturally occurring variants of the Fc region. The amino acid sequence of a non-naturally occurring Fc region (also referred to herein as a "variant Fc region") includes at least one amino acid residue substitution, insertion, and / or deletion compared to the wild-type amino acid sequence. Any new amino acid residues that appear in the sequence of the variant Fc region as a result of insertion or substitution may be referred to as non-naturally occurring amino acid residues. Of note, polymorphisms have been observed at a number of Fc positions, including but not limited to Kabat 270, 272, 312, 315, 356, and 358, and therefore slight differences between the present and prior art sequences may exist.
[0022] As used herein, the term "Fc receptor" or "FcR" is used to refer to a receptor that binds to the Fc region of an antibody. Primary cells that mediate ADCC express FcγRIII, and monocytes express FcγRI, FcγRII, FcγRIII, and / or FcγRIV. FcR expression on hematopoietic cells is described in Ravetch and Kinet, Annu. Rev. Immunol., 9:457-92 (1991). To assess the ADCC activity of a molecule, an in vitro ADCC assay such as that described in U.S. Pat. No. 5,500,362 or U.S. Pat. No. 5,821,337 can be performed. Useful effector cells for such assays include peripheral blood mononuclear cells (PBMC) and natural killer (NK) cells. Alternatively, or in addition, the ADCC activity of the molecule of interest can be evaluated in vivo in an animal model, such as that disclosed in Clynes et al., Proc. Natl. Acad. Sci. (USA), 95:652-656 (1998). As used herein, the term "effector cell" refers to a leukocyte that expresses one or more FcRs and exhibits effector function. The aforementioned cells express at least FcγRI, FcγRII, FcγRIII, and / or FcγRIV and exhibit ADCC effector function. Examples of human leukocytes that mediate ADCC include peripheral blood mononuclear cells (PBMCs), natural killer (NK) cells, monocytes, cytotoxic T cells, and neutrophils.
[0023] As used herein, the term "specificity" refers to the ability of an antibody to detectably bind to a target molecule (e.g., an epitope presented on an antigen) while exhibiting relatively little detectable reactivity with other target molecules.Specificity can be measured relatively, for example, by binding or competitive binding assays using a Biacore instrument, as described elsewhere herein.Specificity can be shown, for example, by the ratio of affinity / avidity of binding to a specific antigen to non-specific binding to other unrelated molecules of about 10:1, about 20:1, about 50:1, about 100:1, 10.000:1 or more.
[0024] The term "affinity" as used herein means the strength of binding of an antibody to a target molecule (e.g., an epitope). The affinity of a binding protein is given by the dissociation constant Kd. For an antibody, the above Kd is defined as [Ab] x [Ag] / [Ab-Ag], where [Ab-Ag] is the molar concentration of the antibody-antigen complex, [Ab] is the molar concentration of unbound antibody, and [Ag] is the molar concentration of unbound antigen. The affinity constant Ka is defined by 1 / Kd. Preferred methods for determining the affinity of binding proteins can be found in Harlow et al., Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (1988), Coligan et al., eds., Current Protocols in Immunology, Greene Publishing Assoc. and Wiley Interscience, NY (1992, 1993), and Muller, Meth. Enzymol. 92:589-601 (1983), which references are incorporated herein by reference in their entireties. One preferred standard method, well known in the art, for determining the affinity of binding proteins is the use of a Biacore instrument.
[0025] As used herein, the term "binding" refers to a direct association between two molecules, for example, by covalent, electrostatic, hydrophobic, and ionic and / or hydrogen bonding interactions, including interactions such as salt bridges and water bridges. In particular, as used herein, the term "binding" in the context of an antibody binding to a given target molecule (e.g., an antigen or epitope) typically refers to a binding that is greater than about 10 -7 M or less, for example, about 10 -8 M or less, for example, about 10 -9 M or less, about 10 -10 M or less, or about 10 more -11 K below M D The binding occurs with an affinity corresponding to
[0026] As used herein, the term "epitope" refers to a specific arrangement of amino acids located in one or more proteins that antibody binds to.Epitope is often composed of chemically active surface groups of molecules such as amino acids or sugar side chains, and has specific three-dimensional structural characteristics and specific charge characteristics.Epitope can be linear or conformational, i.e., it involves two or more amino acid sequences in different regions of antigen that are not necessarily adjacent.
[0027] As used herein, the term "anti-CD95L monoclonal neutralizing antibody" refers to an antibody against a monoclonal antibody that has specificity for CD95L and reduces at least one activity of CD95L. In particular, anti-CD95L monoclonal neutralizing antibody reduces CD95-mediated non-apoptotic signaling pathways and / or reduces CD95-mediated apoptotic signaling pathways. The above-mentioned activities can be measured by any method known in the art, typically as described in the Examples.
[0028] As used herein, the term "JQ3" refers to an antibody having a VL domain as shown in SEQ ID NO:1 and a VH domain as shown in SEQ ID NO:5. SEQ ID NO:2: FR1- CDR1 -FR2- CDR2 -FR3- CDR3 VL domain of JQ3 antibody having the structure of -FR4 QIVFTQSPAIMSAFLGEEITLTCSAS SSVSY MHWYQQKSGTSPKLLIY NTF NLASGVPSRFSGSGSGTFYSLTISSVEAEDAADYYC HQWSSYPT FGGGTKLEIK SEQ ID NO: 6: FR1- CDR1 -FR2- CDR2 -FR3- CDR3 VH domain of JQ3 antibody having the structure of -FR4 EIQLQQTGPELVKPGASVKISCKAS GFSFTDYI MVWVKQSHGKILEWIGD ISPYYGTA TYNLKFKGKATLTVVKSSSTAYMQLNSLTSEDSAVYYC ARAPNRYEVMDY WGQGTSVTVSS
[0029] As used herein, the term "treatment" or "treating" refers to both preventative or suppressive treatments, including treatments of patients at risk of or suspected of having a disease, and patients who have been diagnosed as being ill or suffering from a disease or medical condition, and curative or disease-modifying treatments, including suppression of clinical recurrence. Treatments can be administered to patients who have or may eventually suffer from a medical disorder to prevent, cure, delay the onset of, lessen the severity of, or ameliorate one or more symptoms of a disorder or recurrent disorder, or to extend the patient's survival beyond that expected in the absence of such treatment. "Therapeutic regimen" refers to a pattern of treatment of a disease, such as the pattern of medication used during treatment. Therapeutic regimens can include induction regimens and maintenance regimens. The phrase "induction regimen" or "induction period" refers to a therapeutic regimen (or a portion of a therapeutic regimen) used for early treatment of a disease. The overall purpose of an induction regimen is to provide a high level of drug to the patient during the initial period of the treatment regimen. The induction regimen may use (partially or entirely) a "loading regimen", which may involve administering a higher dose of the drug than the physician would use during a maintenance regimen, administering the drug more frequently than the physician would use during a maintenance regimen, or both. The term "maintenance regimen" or "maintenance period" refers to a treatment regimen (or a portion of a treatment regimen) used for the maintenance of a patient during disease treatment, for example to keep the patient in a state of remission for an extended period of time (months or years). A maintenance regimen may use continuous treatment (e.g., administering a drug at regular intervals, e.g., weekly, monthly, yearly, etc.), or intermittent treatment (e.g., treatment with interruptions, intermittent treatment, treatment at relapse, or treatment upon the fulfillment of certain predefined conditions (e.g., pain, disease symptoms, etc.).
[0030] As used herein, the term "pharmaceutical composition" refers to a composition described herein, or a pharma- ceutically acceptable salt thereof, together with other agents, such as carriers and / or excipients. Pharmaceutical compositions as provided herein typically include a pharma- ceutically acceptable carrier.
[0031] As used herein, "consisting essentially of," in reference to a composition, means that at least one antibody of the invention, as described above, is the only therapeutic or biologically active agent within the composition.
[0032] As used herein, the term "pharmaceutical acceptable carrier" includes any and all solvents, diluents or other liquid vehicles, dispersion or suspension aids, surfactants, isotonicity agents, thickening or emulsifying agents, preservatives, solid binders, lubricants, and the like, as appropriate for the particular dosage form desired. Remington's Pharmaceutical-Sciences, 16th Edition, E. W. Martin (Mack Publishing Co., Easton, Pa., 1980) publishes various carriers used in formulating pharmaceutical compositions, and known techniques for their preparation.
[0033] Antibodies of the Invention The first object of the present invention is to a VL domain comprising the complementarity determining regions CDR1L, CDR2L and CDR3L, wherein CDR1L has the amino acid sequence SSVSY (SEQ ID NO: 3), CDR2L has the amino acid sequence NTF (SEQ ID NO: 4) and CDR3L has the amino acid sequence HQWSSYPT (SEQ ID NO: 5), and - relating to an anti-CD95L monoclonal neutralizing antibody, comprising a VH domain comprising the complementarity determining regions CDR1H, CDR2H and CDR3H, wherein CDR1H has the amino acid sequence GFSFTDYI (SEQ ID NO: 7), CDR2H has the amino acid sequence ISPYYGTA (SEQ ID NO: 8) and CDR3H has the amino acid sequence ARAPNRYEVMDY (SEQ ID NO: 9).
[0034] In some embodiments, the antibodies of the invention are chimeric antibodies.
[0035] In some embodiments, the antibodies of the invention are humanized antibodies.
[0036] In some embodiments, the antibody of the present invention is an antibody fragment. The fragment can be produced by techniques known in the art. For example, Fab or F(ab')2 fragments can be produced by protease digestion of isolated antibodies according to conventional techniques. It is understood that immunoreactive fragments can be modified using known methods, for example, to delay clearance in vivo to obtain a more desirable pharmacokinetic profile, and fragments can be modified with polyethylene glycol (PEG). Methods for coupling PEG to Fab' fragments for site-specific conjugation are described, for example, in Leong et al., Cytokines 16(3):106-119 (2001), and Delgado et al., Br.J.Cancer 5 73(2):175-182 (1996), the disclosures of which are incorporated herein by reference.
[0037] In some embodiments, an antibody of the invention comprises a VL domain having at least 70% identity to SEQ ID NO:1, and / or a VH domain having at least 70% identity to SEQ ID NO:5.
[0038] In some embodiments, the VH and / or VL domains of the antibodies of the present invention contain conservative sequence modifications. The term "conservative sequence modifications" refers to amino acid modifications that do not significantly affect or alter the biological function of the protein that contains the amino acid sequence. Such conservative modifications include amino acid substitutions, additions, and deletions. Modifications can be introduced into proteins by standard techniques known in the art, such as site-directed mutagenesis and PCR-mediated mutagenesis. A "conservative substitution" is one in which an amino acid is replaced with another amino acid having similar properties, such that one skilled in the art of peptide chemistry would expect the secondary structure and hydrophobic properties of the polypeptide to remain substantially unchanged. Thus, amino acid substitutions are generally based on the relative similarity of the amino acid side chain substituents, such as, for example, their hydrophobicity, hydrophilicity, charge, and size. Exemplary substitutions that take into account the various above-mentioned characteristics are well known to those of skill in the art and include arginine and lysine, glutamate and aspartate, serine and threonine, glutamine and asparagine, and valine, leucine, and isoleucine. Amino acid substitutions can also be made based on similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and / or amphipathic properties of the residues. For example, negatively charged amino acids include aspartic acid and glutamic acid, positively charged amino acids include lysine and arginine, and amino acids containing uncharged polar head groups with similar hydrophilicity values include leucine, isoleucine, and valine, glycine and alanine, asparagine and glutamine, and serine, threonine, phenylalanine, and tyrosine. Other groups of amino acids that may represent conservative changes include: (1) ala, pro, gly, glu, asp, gln, asn, ser, thr, (2) cys, ser, tyr, thr, (3) val, ile, leu, met, ala, phe, (4) lys, arg, his, and (5) phe, tyr, trp, his. Families of other amino acid residues with similar side chains have been defined in the art.These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), polar uncharged side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine, tryptophan), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine), beta-branched side chains (e.g., threonine, valine, isoleucine), and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, one or more amino acid residues within an antibody of the invention can be substituted with other amino acid residues from the same side chain family, and the modified antibodies can be tested for binding to CD95L.
[0039] The antibody of the present invention is produced by any technique known in the art, including, but not limited to, any chemical, biological, genetic, or enzymatic technique, alone or in combination. Typically, one skilled in the art can easily produce the above-mentioned antibody by standard techniques for the production of polypeptides, knowing the amino acid sequence of the desired sequence. For example, it can be synthesized using the well-known solid-phase method, preferably using a commercially available peptide synthesizer, such as those manufactured by Applied Biosystems (Foster City, California), following the manufacturer's instructions. Alternatively, the antibody of the present invention can be synthesized by recombinant DNA techniques well known in the art. For example, the antibody can be obtained as a DNA expression product after incorporating a DNA sequence encoding the antibody into an expression vector and introducing such a vector into a suitable eukaryotic or prokaryotic host that is capable of expressing the desired antibody and from which the antibody can then be isolated using well-known methods.
[0040] Therefore, a further object of the present invention relates to a polynucleotide encoding an antibody of the present invention. More specifically, the polynucleotide encodes the VH domain and / or the VL domain of the antibody of the present invention. In some embodiments, the polynucleotide encodes the VH domain or the VL domain of the antibody of the present invention. In some embodiments, the polynucleotide encodes the VH domain and the VL domain of the antibody of the present invention.
[0041] Typically, the polynucleotides described above are DNA or RNA molecules, which can be included in any suitable vector, such as a plasmid, cosmid, episome, artificial chromosome, phage, or viral vector. As used herein, the terms "vector", "cloning vector", and "expression vector" refer to a vehicle that can introduce a DNA or RNA sequence (e.g., a foreign gene) into a host cell to transform the host and enhance the expression (e.g., transcription and translation) of the introduced sequence. Thus, a further object of the present invention relates to a vector comprising the polynucleotide of the present invention. Such a vector can include regulatory elements such as promoters, enhancers, and terminators to express or induce the expression of the above-mentioned antibody upon administration to a subject. Examples of promoters and enhancers used in expression vectors for animal cells include the SV40 early promoter and enhancer, the Moloney murine leukemia virus LTR promoter and enhancer, and the immunoglobulin H chain promoter and enhancer, etc. Any expression vector for animal cells can be used as long as a gene encoding a human antibody C region can be inserted and expressed. Examples of suitable vectors include pAGE107, pAGE103, pHSG274, pKCR, and pSG1βd2-4, etc. Examples of other plasmids include replicative plasmids that contain an origin of replication, or integrative plasmids, such as pUC, pcDNA, and pBR. Examples of other viral vectors include adenovirus, retrovirus, herpes virus, and AAV vectors. Such recombinant viruses can be produced by methods known in the art, such as by transfecting packaging cells, or by transiently transfecting helper plasmids or viruses. Typical examples of viral packaging cells include PA317 cells, PsiCRIP cells, GPenv+ cells, 293 cells, etc.Detailed protocols for producing such replication-defective recombinant viruses can be found, for example, in WO 95 / 14785, WO 96 / 22378, U.S. Pat. No. 5,882,877, U.S. Pat. No. 6,013,516, U.S. Pat. No. 4,861,719, U.S. Pat. No. 5,278,056, and WO 94 / 19478.
[0042] As used herein, the term "promoter / regulatory sequence" refers to a nucleic acid sequence (e.g., a DNA sequence) that is recognized by the cell's or introduced synthetic machinery required to initiate specific transcription of a polynucleotide sequence, thereby allowing expression of a gene product that is operably linked to the promoter / regulatory sequence. In some cases, this sequence may be a core promoter sequence, and in other cases, this sequence may also include enhancer sequences and other regulatory elements required for expression of the gene product. The promoter / regulatory sequence may, for example, be one that expresses a gene product in a tissue-specific manner.
[0043] The term "operably linked" or "transcriptional control" refers to the functional linkage of a heterologous nucleic acid sequence with a regulatory sequence that results in the expression of the heterologous nucleic acid sequence. For example, a first nucleic acid sequence is operably linked to a second nucleic acid sequence when the first nucleic acid sequence is placed in a functional relationship with the second nucleic acid sequence. For example, a promoter is operably linked to a coding sequence when the promoter affects the transcription or expression of the coding sequence. The operably linked DNA sequences can be close to each other, and can be in the same reading frame, for example, when two protein coding regions need to be joined.
[0044] A further object of the present invention relates to host cells transfected, infected or transformed with the polynucleotides and / or vectors according to the invention.
[0045] As used herein, the term "transformation" means the introduction of a "foreign" (i.e., exogenous or extracellular) gene, DNA, or RNA sequence into a host cell so that the host cell expresses the introduced gene or sequence to produce a desired substance, typically a protein or enzyme, encoded by the introduced gene or sequence. A host cell that receives and expresses introduced DNA or RNA has been "transformed."
[0046] The polynucleotides of the present invention can be used to produce the antibodies of the present invention in a suitable expression system.
[0047] The term "expression system" refers to a host cell and a corresponding vector under suitable conditions for expression of a protein, for example, encoded by foreign DNA carried by the vector and introduced into the host cell. Common expression systems include E. coli host cells and a plasmid vector, an insect host cell and a baculovirus vector, and a mammalian host cell and a vector. Other examples of host cells include, without limitation, prokaryotic cells (such as bacteria) and eukaryotic cells (such as yeast cells, mammalian cells, insect cells, plant cells, etc.). Specific examples include E. coli, yeasts of Kluyveromyces or Saccharomyces, mammalian cell lines (e.g., Vero cells, CHO cells, 3T3 cells, COS cells, etc.), and primary or established mammalian cell cultures (e.g., made from lymphoblast cells, fibroblast cells, embryonic cells, epithelial cells, neuronal cells, adipocytes, etc.). Examples also include mouse SP2 / 0-Ag14 cells (ATCC CRL1581), mouse P3X63-Ag8.653 cells (ATCC CRL1580), CHO cells lacking the dihydrofolate reductase gene (hereinafter referred to as "DHFR gene") (Urlaub G et al; 1980), and rat YB2 / 3HL.P2.G11.16Ag.20 cells (ATCC CRL1662, hereinafter referred to as "YB2 / 0 cells"), etc. The present invention also relates to a method for producing a recombinant host cell expressing an antibody of the present invention, the method comprising the steps of (i) introducing the above-mentioned recombinant polynucleotide or vector into a competent host cell in vitro or ex vivo, (ii) culturing the obtained recombinant host cell in vitro or ex vivo, and (iii) optionally selecting a cell expressing and / or secreting the above-mentioned antibody. Such recombinant host cells can be used to produce the antibodies of the invention.
[0048] Examples of vectors include all those known in the art, including, without limitation, cosmids, plasmids (e.g., naked or contained in liposomes), and viruses (e.g., lentiviruses, retroviruses, adenoviruses, and adeno-associated viruses) incorporating the recombinant polynucleotide.
[0049] The antibodies of the invention are suitably separated from the culture medium by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.
[0050] In some embodiments, the antibodies of the invention (preferably monoclonal antibodies) do not comprise an Fc region that mediates antibody-dependent cell-mediated cytotoxicity and therefore do not comprise an Fc moiety that induces antibody-dependent cellular cytotoxicity (ADCC). In some embodiments, the antibodies of the invention (preferably monoclonal antibodies) do not comprise an Fc region that induces complement-dependent cytotoxicity (CDC) or antibody-dependent phagocytosis. In some embodiments, the antibodies of the invention (preferably monoclonal antibodies) do not directly or indirectly result in depletion of cells expressing a CD95L polypeptide (e.g., CD95L +In some embodiments, the antibodies (preferably monoclonal antibodies) of the invention do not comprise an Fc domain capable of substantially binding to an FcγRIIIA (CD16) polypeptide. In some embodiments, the antibodies (preferably monoclonal antibodies) of the invention do not comprise an Fc domain (e.g., no CH2 and / or CH3 domain) or comprise an Fc domain of an IgG2 or IgG4 isotype. In some embodiments, the antibodies (preferably monoclonal antibodies) of the invention comprise an Fc domain (e.g., of an IgG1) with an altered glycosylation profile, eliminating ADCC activity of the antibody. In some embodiments, the antibodies (preferably monoclonal antibodies) of the invention consist of or comprise a Fab, Fab', Fab'-SH, F(ab')2, Fv, diabody, single chain antibody fragment, or a multispecific antibody comprising multiple different antibody fragments. In some embodiments, the antibodies (preferably monoclonal antibodies) of the invention are not linked to a toxic moiety. In some embodiments, one or more selected amino acids from the amino acid residues can be replaced with a different amino acid residue such that the antibody has altered C2q binding and / or reduced or eliminated CDC. This approach is described in further detail in U.S. Patent No. 6,194,551 by Idusogie et al.
[0051] Therapeutic Use Thus, a further object of the present invention relates to an antibody of the present invention for use as a medicament. More specifically, the present invention provides a method of treatment in a patient in need of treatment, said method comprising administering to the patient a therapeutically effective amount of an antibody of the present invention.
[0052] In some embodiments, the antibodies of the invention are specifically intended to treat cancer in a subject in need of such treatment.
[0053] As used herein, the term "cancer" has its general meaning in the art, including, but not limited to, solid tumors and blood-borne tumors. The term cancer includes diseases of the skin, tissues, organs, bone, cartilage, blood, and blood vessels. The term "cancer" further includes both primary and metastatic cancers. Examples of cancers that can be treated by the methods and compositions of the present invention include, but are not limited to, cancer cells of the bladder, blood, bone, bone marrow, brain, breast, colon, esophagus, gastrointestinal tract, gums, head, kidney, liver, lung, nasopharynx, cervix, ovary, prostate, skin, stomach, testis, tongue, or uterus. In addition, the cancer may be specifically of the following histological types, but is not limited to: malignant neoplasm, carcinoma, undifferentiated carcinoma, giant cell and spindle cell carcinoma, small cell carcinoma, papillary carcinoma, squamous cell carcinoma, lymphoepithelial carcinoma, basal cell carcinoma, hair matrix carcinoma, transitional cell carcinoma, papillary transitional cell carcinoma, adenocarcinoma, malignant gastrinoma, cholangiocarcinoma, hepatocellular carcinoma, mixed hepatocellular carcinoma and cholangiocarcinoma, trabecular adenocarcinoma, adenoid cystic carcinoma, adenocarcinoma in adenomatous polyps, familial polyposis coli adenocarcinoma, solid tumors, malignant carcinoid tumors, branchio-alveolar adenocarcinoma, papillary adenocarcinoma, chromophobe carcinoma, eosinophilic carcinoma, acidophilic adenocarcinoma, basophilic carcinoma, clear cell adenocarcinoma, granular cell carcinoma, follicular adenocarcinoma, papillary and follicular adenocarcinoma, nonencapsulated sclerosing carcinoma, adrenal cortical carcinoma, endometrioid carcinoma,carcinoma), skin adnexal carcinoma, apocrine gland carcinoma, sebaceous gland carcinoma, earwax gland carcinoma, mucinous epidermoid carcinoma, cystadenocarcinoma, papillary cystadenocarcinoma, papillary serous cystadenocarcinoma, mucinous cystadenocarcinoma, mucinous adenocarcinoma, signet ring cell carcinoma, invasive ductal carcinoma, medullary carcinoma, lobular carcinoma, inflammatory carcinoma, Paget's disease of the breast, acinic cell carcinoma, adenosquamous carcinoma, adenocarcinoma with squamous metaplasia, malignant thymoma, malignant ovarian stromal tumor, malignant thecal tumor, malignant granulosa cell tumor, Malignant neuroblastoma (roblastoma), Sertoli cell carcinoma, malignant Leydig cell tumor, malignant lipocytoma, malignant paraganglioma, malignant extramammary paraganglioma, pheochromocytoma, glomus angiosarcoma, malignant melanoma, amelanotic melanoma, superficial spreading melanoma, malignant melanoma in giant pigmented nevus, epithelioid cell melanoma, malignant blue nevus, sarcoma, fibrosarcoma, malignant fibrous histiocytoma, myxosarcoma, liposarcoma tumor, leiomyosarcoma, rhabdomyosarcoma, embryonal rhabdomyosarcoma, alveolar rhabdomyosarcoma, stromal sarcoma, malignant mixed tumor, mixed Müllerian tumor, nephroblastoma, hepatoblastoma, carcinosarcoma, malignant mesenchymoma, malignant Brenner tumor, malignant phyllodes tumor, synovial sarcoma, malignant mesothelioma, dysgerminoma, embryonal carcinoma, malignant teratoma, malignant ovarian thyroid tumor, choriocarcinoma, malignant mesothelioma, angiosarcoma, malignant hemangioendothelioma, Kaposi's sarcoma, malignant hemangiopericytoma, lymphangiosarcoma, bone Sarcoma, Parosteal Osteosarcoma, Chondrosarcoma, Malignant Chondroblastoma, Mesenchymal Chondrosarcoma, Giant Cell Tumor of Bone, Ewing's Sarcoma, Malignant Odontogenic Tumor, Ameloblastic Odontosarcoma, Malignant Ameloblastic Tumor, Ameloblastic Fibrosarcoma, Malignant Pinealoma, Chordoma, Malignant Glioma, Ependymoma, Astrocytoma, Protoplasmic Astrocytoma, Fibrous Astrocytoma, Astroblastoma, Glioblastoma, Oligodendroglioma, Primitive Neuroectodermal Tumorneuroectodermal), cerebellar sarcoma, ganglioneuroblastoma, neuroblastoma, retinoblastoma, olfactory neurogenic tumor, malignant meningioma, neurofibrosarcoma, malignant neurilemmoma, malignant granular cell tumor, malignant lymphoma, Hodgkin's disease, Hodgkin's lymphoma, lateral granuloma, malignant small lymphocytic lymphoma, malignant diffuse large cell lymphoma, malignant follicular lymphoma, mycosis fungoides, other Specified non-Hodgkin's lymphoma, malignant histiocytosis, multiple myeloma, mast cell sarcoma, immunoproliferative small intestinal disease, leukemia, lymphocytic leukemia, plasma cell leukemia, erythroleukemia, lymphosarcoma cell leukemia, myeloid leukemia, basophilic leukemia, eosinophilic leukemia, monocytic leukemia, mast cell leukemia, megakaryoblastic leukemia, myeloid sarcoma, and hairy cell leukemia.
[0054] In some embodiments, the subject is afflicted with a cancer selected from the group consisting of breast cancer, colon cancer, lung cancer, prostate cancer, testicular cancer, brain cancer, skin cancer, rectal cancer, gastric cancer, esophageal cancer, sarcoma, tracheal cancer, head and neck cancer, pancreatic cancer, liver cancer, ovarian cancer, lymphatic cancer, cervical cancer, vulvar cancer, melanoma, mesothelioma, kidney cancer, bladder cancer, thyroid cancer, bone cancer, carcinoma, sarcoma, and soft tissue cancer.
[0055] In some embodiments, the antibody of the present invention is specifically for treating triple-negative breast cancer.As used herein, the expression "triple-negative breast cancer" has its general meaning in the art, and means that the breast cancer lacks or expresses low levels of the receptors for the hormones estrogen (ER negative) and progesterone (PR negative) and the protein HER2.
[0056] In some embodiments, the antibodies of the invention are specifically for the prevention of metastasis (eg, in subjects suffering from triple-negative breast cancer).
[0057] In some embodiments, the antibodies of the invention are specifically for the treatment of inflammatory diseases. In some embodiments, the inflammatory diseases are selected from the group consisting of arthritis, rheumatoid arthritis, acute arthritis, chronic rheumatoid arthritis, gouty arthritis, acute gouty arthritis, chronic inflammatory arthritis, degenerative arthritis, infectious arthritis, Lyme arthritis, proliferative arthritis, psoriatic arthritis, vertebral arthritis, and juvenile onset rheumatoid arthritis, osteoarthritis, chronic progressive arthritis, osteoart ... deformans), chronic primary polyarthritis, reactive arthritis, and ankylosing spondylitis, inflammatory hyperproliferative skin diseases, psoriasis, e.g., plaque psoriasis, guttate psoriasis, pustular psoriasis, and nail psoriasis, dermatitis including contact dermatitis, chronic contact dermatitis, allergic dermatitis, allergic contact dermatitis, dermatitis herpetiformis, and atopic dermatitis, X-linked hyper IgM syndrome, chronic autoimmune urticaria, urticaria, e.g., chronic Allergic urticaria and chronic idiopathic urticaria, polymyositis / dermatomyositis, juvenile dermatomyositis, toxic epidermal necrolysis, scleroderma, systemic sclerosis, sclerosis, systemic sclerosis, multiple sclerosis (MS), spino-optical MS, primary progressive MS (PPMS), and relapsing-remitting MS (RRMS), progressive systemic sclerosis, atherosclerosis, arteriosclerosis, sclerosis disseminata, and ataxic sclerosis, inflammatory bowel disease (IBD), Crohn's disease, colitis, ulcerative colitis, colitis ulcerosa, microscopic colitis, collagenous colitis, polypoid colitis polyposa), necrotizing enterocolitis, transmural colitis, autoimmune inflammatory bowel disease, pyoderma gangrenosum, erythema nodosum, primary sclerosing cholangitis, episcleritis, respiratory distress syndrome, adult or acute respiratory distress syndrome (ARDS), meningitis, inflammation of all or part of the uvea, iritis, choroiditis, autoimmune blood diseases, rheumatoid spondylitis, sudden hearing loss, IgE-mediated diseases such as anaphylaxis, and allergic and atopic rhinitis, encephalitis, Rasmussen's encephalitis, limbic and / or brainstem encephalitis, uveitis, anterior uveitis, acute anterior uveitis,Granulomatous uveitis, non-granulomatous uveitis, phacoantigenic uveitis, posterior uveitis, autoimmune uveitis, glomerulonephritis (GN), idiopathic membranous GN or idiopathic membranous nephropathy, membrano proliferative or membranous proliferative GN (MPGN), rapidly progressive GN, allergic conditions, autoimmune myocarditis, leukocyte adhesion deficiency, systemic lupus erythematosus (SLE), systemic lupus erythematodes, e.g. cutaneous SLE, subacute cutaneous lupus erythematosus, neonatal lupus syndrome (NLE), generalized lupus erythematosus disseminatus), lupus (including nephritis, encephalitis, pediatric, non-renal, extrarenal, discoid, alopecia), juvenile-onset (type I) diabetes mellitus including insulin-dependent diabetes mellitus of childhood (IDDM), adult-onset (type II) diabetes mellitus, autoimmune diabetes mellitus, idiopathic diabetes insipidus, immune responses related to acute and delayed hypersensitivity mediated by cytokines and T lymphocytes, tuberculosis, sarcoidosis, granulomatosis, lymphomatoid granulomatosis, Wegener's granulomatosis, agranulocytosis, vasculitis, large vasculitis, rheumatoid polyposis Myalgia, giant cell (Takayasu) arteritis, medium-sized vasculitis, Kawasaki disease, polyarteritis nodosa, microscopic polyarteritis, CNS vasculitis, necrotizing, cutaneous, hypersensitivity vasculitis, systemic necrotizing vasculitis, and ANCA-associated vasculitis, such as Churg-Strauss vasculitis or syndrome (CSS), including temporal arteritis; aplastic anemia, autoimmune aplastic anemia, Coombs positive anemia, Diamond-Blackfan anemia, hemolytic anemia, or immune hemolytic anemia, including autoimmune hemolytic anemia (AIHA); pernicious anemia antigen-antibody complex-mediated diseases, such as pernicious anemia (anemia perniciosa), Addison's disease, pure red cell anemia or pure red cell aplasia (PRCA), factor VIII deficiency, hemophilia A, autoimmune neutropenia, pancytopenia, leukopenia, diseases involving leukocyte emigration, CNS inflammatory disorders, multiple organ injury syndromes, e.g. secondary to sepsis, trauma, or hemorrhage;Antiglomerular basement membrane disease, antiphospholipid syndrome, allergic neuritis, Bechet's or Behcet's disease, Castleman syndrome, Goodpasture's syndrome, Raynaud's syndrome, Sjogren's syndrome, Stevens-Johnson syndrome, pemphigoid, e.g. bullous pemphigoid and cutaneous pemphigoid, pemphigus, optionally pemphigus vulgaris, pemphigus foliaceus, mucous membrane pemphigoid, pemphigus erythematosus, autoimmune polyendocrinopathy, Reiter's disease or syndrome, immune complex nephritis, antibodies Interstitial nephritis, neuromyelitis optica, polyneuropathy, chronic neuropathy, IgM polyneuropathy, IgM-mediated neuropathy, thrombocytopenia, thrombotic thrombocytopenic purpura (TTP), idiopathic thrombocytopenic purpura (ITP), autoimmune orchitis and oophoritis, primary hypothyroidism, hypoparathyroidism, autoimmune thyroiditis, Hashimoto's disease, chronic thyroiditis (Hashimoto's thyroiditis), subacute thyroiditis, autoimmune thyroid disease, idiopathic hypothyroidism, Graves' disease, polyglandular syndrome , e.g. autoimmune polyglandular syndromes (or polyendocrine syndromes), paraneoplastic syndromes including neurological paraneoplastic syndromes, e.g. Lambert-Eaton myasthenic syndrome or Eaton-Lambert syndrome, stiff-man or stiff-person syndrome, encephalomyelitis, allergic encephalomyelitis, experimental allergic encephalomyelitis (EAE), myasthenia gravis, thymoma-associated myasthenia gravis, cerebellar degeneration, neuromyotonia, opsoclonus or opsoclonus-myoclonus syndrome (OMS) , and sensory neuropathy, multifocal motor neuropathy, Sheehan's syndrome, autoimmune hepatitis, chronic hepatitis, lupoid hepatitis, giant cell hepatitis, chronic active hepatitis or autoimmune chronic active hepatitis, lymphocytic interstitial pneumonia, bronchiolitis obliterans (non-transplant) and NSIP, Guillain-Barré syndrome, Berger's disease (IgA nephropathy), idiopathic IgA nephropathy, linear IgA dermatosis, primary biliary cirrhosis, pneumonocirrhosis, autoimmune enteropathy syndrome, celiac disease disease), Coeliac disease, celiac sprue (gluten enteropathy), refractory sprue, idiopathic sprue, cryoglobulinemia, amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease), coronary artery disease, autoimmune ear diseases such as autoimmune inner ear disease (AGED), autoimmune hearing loss, etc.opsoclonus-myoclonus syndrome (OMS), polychondritis, such as refractory or relapsing polychondritis, pulmonary alveolar proteinosis, amyloidosis, scleritis, non-cancerous lymphocytosis, monoclonal B-cell lymphocytosis, optionally primary lymphocytosis including benign monoclonal gammopathy or monoclonal gammopathy of undetermined significance (MGUS), peripheral neuropathy, paraneoplastic syndromes, channelopathies, such as epilepsy, migraine, arrhythmias, myopathy, hearing loss, blindness, periodic paralysis, and channelopathies of the CNS, autism, inflammatory myopathy, focal segmental glomerulosclerosis (FSGS), endocrine ophthalmopathy, uveitis retina, retinitis chorioretinitis, autoimmune hepatopathy, fibromyalgia, polyendocrine deficiency, Schmidt's syndrome, adrenal gland syndrome, Nephritis, gastroatrophy, presenile dementia, demyelinating diseases such as autoimmune demyelinating diseases, diabetic nephropathy, Dressler's syndrome, alopecia areata, CREST syndrome (calcinosis, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasia), male and female autoimmune infertility, mixed connective tissue disease, Chagas' disease, rheumatic fever, recurrent pregnancy loss, farmer's lung, erythema multiforme, postpericardiotomy syndrome, Cushing's syndrome, bird breeder's disease, allergic granulomatous vasculitis, benign lymphocytic vasculitis, Alport's syndrome, alveolitis such as allergic alveolitis and fibrosing alveolitis, interstitial lung disease, transfusion reactions, leprosy, malaria, leishmaniasis, kypanosomiasis, schistosomiasis, ascariasis, aspergillosis, Sampter's syndrome syndrome), Kaplan's syndrome, dengue fever, endocarditis, endomyocardial fibrosis, diffuse interstitial pulmonary fibrosis, interstitial pulmonary fibrosis, idiopathic pulmonary fibrosis, cystic fibrosis, endophthalmitis, erythema elevatum et diutinum, erythroblastosis fetalis, eosinophilic fasciitis, Charmant's syndrome, Felty's syndrome, filariasis, cyclitis, such as chronic cyclitis, heterochromatic cyclitis, iridocyclitis, or Fuchs' cyclitis, Henoch-Schönlein purpura, human immunodeficiency virus (HIV) infection, echovirus infection, cardiomyopathy, Alzheimer's disease, parvovirus infection, rubella virus infection, post-vaccination syndrome, congenital rubella infection, Epstein-Barr virus infection, mumps, Evans' syndrome, autoimmune gonadal dysfunction, Sydenham's chorea,Poststreptococcal nephritis, thromboangitis ubiterans, thyrotoxicosis, spinal fistula, choroiditis, giant cell polymyalgia, endocrine ophthalmopathy, chronic hypersensitivity pneumonitis, keratoconjunctivitis sicca, epidemic keratoconjunctivitis, idiopathic nephritic syndrome, minimal change nephropathy, benign familial and ischemia-reperfusion injury, retinal autoimmunity, arthritis, bronchitis, chronic obstructive airway disease, silicosis, aphthous stomatitis, arteriosclerotic disorders, aspermiogenese, autoimmune hemolysis, Beck's disease, cryoglobulinemia, Dupuytren's contracture, endophthalmia phacoanaphylactica, allergic enterocolitis, leprous erythema nodosum, idiopathic facial nerve palsy, chronic fatigue syndrome, rheumatic fever (febris rheumatica, Hamman-Rich disease, sensorineural deafness, paroxysmal hemoglobinuria paroxysmatica, hypogonadism, ileitis regionalis, leukopenia, infectious mononucleosis infectiosa, transverse myelitis, primary idiopathic myxedema, nephrosis, ophthalmia symphatica, granulomatous orchitis, pancreatitis (e.g. chronic pancreatitis), polyradiculitis acuta, pyoderma gangrenosum, Kervan thyroiditis, acquired splenic atrophy, antispermatozoan antibodies antobody), non-malignant thymoma, vitiligo, SCID and Epstein-Barr virus-related diseases, acquired immune deficiency syndrome (AIDS), parasitic diseases such as leishmaniasis, toxic shock syndrome, food poisoning, conditions involving T cell infiltration, leukocyte adhesion deficiency, immune responses related to cytokines and T lymphocyte-mediated acute and delayed hypersensitivity, diseases involving leukocyte emigration, multiple organ injury syndrome, antigen-antibody complex-mediated diseases, anti-glomerular basement membrane disease, allergic neuritis, autoimmune polyendocrinopathy, oophoritis, primary myxedema, autoimmune atrophic gastritis, sympathetic ophthalmia, rheumatic diseases, mixed connective tissue disease, nephrotic syndrome, insulitis, polyglandular insufficiency, peripheral neuropathy, autoimmune polyglandular syndrome type I, adult-onset idiopathic hypoparathyroidism (AOIH), alopecia totalis, dilated cardiomyopathy,Epidermolysis bullosa acquisita (EBA), hemochromatosis, myocarditis, nephrotic syndrome, primary sclerosing cholangitis, suppurative or non-suppurative sinusitis, acute or chronic sinusitis, ethmoid sinusitis, frontal sinusitis, maxillary sinusitis, or sphenoid sinusitis, eosinophil-related diseases such as eosinophilia, pulmonary infiltrative eosinophilia, Eosinophilia-myalgia syndrome, Löffler's syndrome, chronic eosinophilic pneumonia, tropical pulmonary eosinophilia, bronchopulmonary aspergillosis, aspergilloma, or eosinophil-containing granuloma, anaphylaxis, seronegative spondyloarthritis, polyglandular autoimmune disease, sclerosing cholangitis, scleritis, episcleritis, chronic mucocutaneous candidiasis, Bruton's syndrome, transient hypogammaglobulinemia of infancy, Wiskott-Aldrich syndrome, ataxia-telangiectasia, autoimmune diseases associated with connective tissue diseases, rheumatism, neurological diseases, ischemia-reperfusion injury, hyporesponsiveness to blood pressure, vascular dysfunction, antgiectasis, tissue injury, cardiovascular ischemia, pain sensation hypersensitivity, cerebral ischemia, and diseases involving angiogenesis, allergic hypersensitivity disorders, glomerulonephritides, reperfusion injury, reperfusion injury of the myocardium or other tissues, skin diseases with an acute inflammatory component, acute purulent meningitis, or other central nervous system inflammatory disorders, ocular and orbital inflammatory disorders, granulocyte transfusion associated syndrome, cytokine-induced toxicity, acute intense inflammation, chronic refractory inflammation, pyelitis, pneumonocirrhosis, diabetic retinopathy, diabetic aortopathy, endarterial hyperplasia, peptic ulcer, valvulitis, and endometriosis.
[0058] In some embodiments, the antibodies of the invention are particularly suitable for the treatment of systemic lupus erythematosus or antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV).
[0059] In some embodiments, the antibodies of the invention are particularly suitable for the treatment of viral-induced inflammation, in particular COVID19.
[0060] Pharmaceutical Compositions A further object of the present invention relates to a composition comprising, consisting of or consisting essentially of an antibody of the present invention.
[0061] In some embodiments, the composition of the invention is a pharmaceutical composition and further comprises a pharma- ceutically acceptable carrier.
[0062] The pharma- ceutically acceptable carriers that can be used in the composition include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of vegetable saturated fatty acids, water, salts or electrolytes such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinylpyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol, and wool fat.For use in administering to a patient, the composition can be formulated for administration to a patient.The composition of the present invention can be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, bucally, vaginally, or via an indwelling reservoir. As used herein, it includes subcutaneous, intravenous, intramuscular, intra-articular, intrasynovial, intrasternal, intrathecal, intrahepatic, intralesional, and intracranial injection or infusion techniques. The sterile injectable form of the composition of the present invention can be an aqueous or oily suspension. These suspensions can be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation can also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that can be used are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile fixed oils are conventionally used as a solvent or suspending medium. For this purpose, any bland fixed oil can be used, including synthetic mono- or diglycerides. Fatty acids, such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharma- ceutical-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions.These oil solutions or suspensions may also contain long-chain alcohol diluents or dispersants, such as carboxymethylcellulose or similar dispersants, commonly used in the formulation of pharma- ceutically acceptable dosage forms, including emulsions and suspensions. Other commonly used surfactants, such as Tween, Span, and other emulsifiers or bioavailability enhancers commonly used in the manufacture of pharma-ceutically acceptable solid, liquid, or other dosage forms, may also be used for formulation purposes. The compositions of the present invention may be orally administered in any orally acceptable dosage form, including, but not limited to, capsules, tablets, aqueous suspensions, or solutions. In the case of tablets for oral use, commonly used carriers include lactose and cornstarch. Lubricants, such as magnesium stearate, are also typically added. For oral administration in capsule form, useful diluents include, for example, lactose. When aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweeteners, flavors, or coloring agents may also be added. Alternatively, the compositions of the present invention can be administered in the form of suppositories for rectal administration. These can be prepared by mixing the drug with a suitable non-irritating excipient that is solid at room temperature but liquid at rectal temperature, and therefore dissolves in the rectum to release the drug. Such materials include cocoa butter, beeswax, and polyethylene glycol. The compositions of the present invention can also be administered topically, especially when the target of treatment includes areas or organs that are easily accessible by topical application, including diseases of the eye, skin, or lower intestinal tract. Suitable topical formulations are easily prepared for each of these areas or organs. For topical application, the compositions can be formulated into a suitable ointment containing the active ingredient suspended or dissolved in one or more carriers. Carriers for topical administration of the compounds of the present invention include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compounds, emulsifying wax, and water.Alternatively, the compositions can be formulated into a suitable lotion or cream containing the active ingredient suspended or dissolved in one or more pharma- ceutically acceptable carriers. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol, and water. Topical application for the lower intestinal tract can be with a rectal suppository (see above) or a suitable enema formulation. Patches can also be used. The compositions of the present invention can also be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques well known in the art of pharmaceutical formulation and can be prepared as a solution in saline using benzyl alcohol or other suitable preservatives, absorption enhancers to enhance bioavailability, fluorocarbons, and / or other conventional solubilizing or dispersing agents. For example, the antibody present in the pharmaceutical composition of the present invention can be provided at a concentration of 10 mg / mL in either 100 mg (10 mL) or 500 mg (50 mL) single-use vials. The product is formulated for intravenous administration in 9.0 mg / mL sodium chloride, 7.35 mg / mL sodium citrate dihydrate, 0.7 mg / mL polysorbate 80, and sterile water for injection. The pH is adjusted to 6.5. An example of a suitable dosage range for the antibody in the pharmaceutical composition of the invention is about 1 mg / m. 2 ~500mg / m 2 However, it is understood that these plans are exemplary, and optimal plans and regimens can be adapted taking into account the affinity and tolerability of a particular antibody in the pharmaceutical composition, which needs to be determined in clinical trials. The pharmaceutical composition of the present invention for injection (e.g., intramuscular, intravenous) can be prepared to contain sterile buffer water (e.g., 1 ml for intramuscular injection) and about 1 ng to about 100 mg, for example, about 50 ng to about 30 mg or more, preferably about 5 mg to about 25 mg of the antibody of the present invention.
[0063] The present invention is further illustrated by the following figures and examples, which should not, however, be construed in any way as limiting the scope of the present invention. EXAMPLES
[0064] method Generation of anti-CD95L monoclonal neutralizing antibody JQ3 Balb / c mice were immunized and boosted repeatedly with recombinant soluble CD95L (Peprotech) via the intrasplenic route. Serum was collected and immune response efficiency was evaluated by ELISA using IgCD95L-coated plates. Spleen cells from the mice that showed the highest titers were fused with mouse SP2 / O-Ag14 cell line mouse (DSMZ,ACC146) and selected to generate antibody-producing hybridomas. Hybridomas producing CD95L-targeted IgG were selected based on their ability to bind IgCD95L immobilized on microtiter plates and then verified using flow cytometry against CD95L-expressing 1A12 cells. After a cloning step, monoclonal antibody JQ3 was selected, produced in roller bottles and purified on a protein A column (GE).
[0065] Measurement of cell death Cell viability was assessed using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay as previously described ( 48 ). Briefly, medium containing 100 ng / mL IgCD95L (i.e., the concentration of IgCD95L that induces 100% cell death in Jurkat T cells) was preincubated with the indicated concentrations of JQ3, NOK-1, or control antibodies for 30 min and then incubated with Jurkat T cells (4.10 μg / mL) in a final volume of 100 μL in flat-bottom 96-well plates. 4) for 24 h. MTT (15 μl at 5 mg / mL in PBS) was then added and incubated at 37° C. for 4 h, after which the absorbance was measured at a wavelength of 570 nm using an Infinite200Pro (Tecan, Maennedorf, Switzerland).
[0066] DMSO-treated HL60 cells To induce neutrophilic differentiation of the HL60 cell line, log-phase cells were resuspended in complete RPMI1640 growth medium containing 1.25% DMSO for 24–96 h.
[0067] Imaging of calcium concentration ([Ca 2+ ]i) We performed single-cell cytoplasmic calcium imaging using a novel fluorogenic calcium-sensitive dye, Cal-520. Cal-520 has low basal fluorescence and is sensitive to [Ca 2+ It has been shown to be the best performing green-emitting dye, as it exhibits a large increase in fluorescence in response to small changes in Ca, resulting in a good signal-to-noise ratio (44). 2+ The probe exhibits better intracellular retention than other calcium dyes. Cells were loaded with Cal-520 (2 μM) in Hank's balanced salt solution (HBSS) for 30 min at room temperature (20–25°C). Cells were centrifuged to remove extracellular probe, rinsed with HBSS, and incubated for 15 min to complete deesterification of the dye. The loaded cells were deposited on a glass coverslip placed in a recording chamber located on the stage of an inverted epifluorescence microscope (Olympus IX70) equipped with a 40x UApo / 340-1.15W water immersion objective (Olympus, Tokyo, Japan). A 4 × 4 binning function was used to minimize UV light exposure. Cal-520 was loaded onto a glass coverslip placed in a recording chamber located on the stage of an inverted epifluorescence microscope (Olympus IX70) equipped with a 40x UApo / 340-1.15W water immersion objective (Olympus, Tokyo, Japan). + / - Excitation was performed at 22 nm, and 530 images were captured at regular 10-second intervals with 12-bit resolution by a high-speed scanning camera (CoolSNAP fx Monochrome, Photometrics). + / -Images were acquired at 30 nm. Regions of interest were obtained in specific recorded cells to restrict data collection to specific regions. Imaging was controlled by Universal Imaging software including Metafluor and Metamorph. Changes in fluorescence intensity were normalized to the initial fluorescence value F0 (pixel averaged over 20 frames before stimulation) and expressed as F / F0 (relative [Ca 2+ ] cyt (Figure 1C). One field was acquired from each coverslip, and data were pooled from six independent coverslips on three separate days.
[0068] result We generated an anti-CD95L monoclonal neutralizing antibody (mAb) called JQ3 (IgG1κ). The characteristics of the antibody are described in Figure 1A, Figure 1B, and Figure 1C. Notably, we confirmed the neutralizing effect of JQ3, as this homemade monoclonal antibody inhibited the CD95-mediated apoptosis signaling pathway induced in the T cell line Jurkat more efficiently than NOK-1mAb (Figure 1D). Interestingly, JQ3 inhibited CD95-mediated Ca2+ expression in neutrophils isolated from healthy donors and stimulated with serum isolated from patients suffering from various inflammatory diseases, including COVID19 and antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV). 2+ The response was blocked (Figure 2).
[0069] References Throughout this application, various references describe the state of the art to which this invention pertains. The disclosures of these references are incorporated herein by reference into this disclosure.
Claims
1. a VL domain comprising the complementarity determining regions CDR1L, CDR2L and CDR3L, wherein said CDR1L has the amino acid sequence SSVSY (SEQ ID NO: 3), said CDR2L has the amino acid sequence NTF (SEQ ID NO: 4) and said CDR3L has the amino acid sequence HQWSSYPT (SEQ ID NO: 5), and - a VH domain comprising the complementarity determining regions CDR1H, CDR2H and CDR3H, wherein said CDR1H has the amino acid sequence GFSFTDYI (SEQ ID NO: 7), said CDR2H has the amino acid sequence ISPYYGTA (SEQ ID NO: 8) and said CDR3H has the amino acid sequence ARAPNRYEVMDY (SEQ ID NO: 9).
2. It is a chimeric antibody, The anti-CD95L monoclonal neutralizing antibody of claim 1.
3. A humanized antibody. The anti-CD95L monoclonal neutralizing antibody of claim 1.
4. comprising a VL domain having at least 70% identity to SEQ ID NO:1 and / or a VH domain having at least 70% identity to SEQ ID NO:5; The anti-CD95L monoclonal neutralizing antibody of claim 1.
5. The VH domain and / or the VL domain of the antibody of the invention contain conservative sequence modifications. The anti-CD95L monoclonal neutralizing antibody of claim 1.
6. A polynucleotide encoding the anti-CD95L monoclonal neutralizing antibody of claim 1.
7. A polynucleotide according to claim 6, encoding the VH domain and / or the VL domain of the anti-CD95L monoclonal neutralizing antibody according to claim 1.
8. A vector comprising the polynucleotide of claim 6.
9. A host cell transfected, infected or transformed with a polynucleotide according to claim 6 and / or a vector according to claim 8.
10. For use as a medicine, The anti-CD95L monoclonal neutralizing antibody of claim 1.
11. A method of treatment in a patient in need of treatment, comprising administering to the patient a therapeutically effective amount of the anti-CD95L monoclonal neutralizing antibody of claim 1.
12. A method of treating cancer in a patient in need of treatment, comprising administering to the patient a therapeutically effective amount of an anti-CD95L monoclonal neutralizing antibody described in claim 1.
13. The patient is suffering from a cancer selected from the group consisting of breast cancer, colon cancer, lung cancer, prostate cancer, testicular cancer, brain cancer, skin cancer, rectal cancer, gastric cancer, esophageal cancer, sarcoma, tracheal cancer, head and neck cancer, pancreatic cancer, liver cancer, ovarian cancer, lymphatic cancer, cervical cancer, vulvar cancer, melanoma, mesothelioma, kidney cancer, bladder cancer, thyroid cancer, bone cancer, carcinoma, sarcoma, and soft tissue cancer; The method of claim 12.
14. The patient is afflicted with triple-negative breast cancer. The method of claim 12.
15. A method of treating an inflammatory disease in a patient in need of treatment, comprising administering to the patient a therapeutically effective amount of an anti-CD95L monoclonal neutralizing antibody according to claim 1.
16. The inflammatory diseases include arthritis, rheumatoid arthritis, acute arthritis, chronic rheumatoid arthritis, gouty arthritis, acute gouty arthritis, chronic inflammatory arthritis, degenerative arthritis, infectious arthritis, Lyme arthritis, proliferative arthritis, psoriatic arthritis, vertebral arthritis, and juvenile onset rheumatoid arthritis, osteoarthritis, chronic progressive arthritis, osteoarthritis, and osteoarthritis. deformans), chronic primary polyarthritis, reactive arthritis, and ankylosing spondylitis, inflammatory hyperproliferative skin diseases, psoriasis, e.g., plaque psoriasis, guttate psoriasis, pustular psoriasis, and ungual psoriasis, dermatitis including contact dermatitis, chronic contact dermatitis, allergic dermatitis, allergic contact dermatitis, dermatitis herpetiformis, and atopic dermatitis, X-linked hyper IgM syndrome, urticaria, including chronic autoimmune urticaria, e.g., chronic Allergic urticaria and chronic idiopathic urticaria, polymyositis / dermatomyositis, juvenile dermatomyositis, toxic epidermal necrolysis, scleroderma, systemic sclerosis, sclerosis, systemic sclerosis, multiple sclerosis (MS), spino-optical MS, primary progressive MS (PPMS), and relapsing remitting MS (RRMS), progressive systemic sclerosis, atherosclerosis, arteriosclerosis, sclerosis disseminata, and ataxic sclerosis, inflammatory bowel disease (IBD), Crohn's disease, colitis, ulcerative colitis, ulcerative colitis (colitis ulcerosa), microscopic colitis, collagenous colitis, polypoid colitis (colitis polyposa), necrotizing enterocolitis, transmural colitis, autoimmune inflammatory bowel disease, pyoderma gangrenosum, erythema nodosum, primary sclerosing cholangitis, episcleritis, respiratory distress syndrome, adult or acute respiratory distress syndrome (ARDS), meningitis, inflammation of all or part of the uvea, iritis, choroiditis, autoimmune blood diseases, rheumatoid spondylitis, sudden deafness, IgE-mediated diseases such as anaphylaxis, and allergic and atopic rhinitis, encephalitis, Rasmussen's encephalitis, limbic encephalitis and / or brainstem encephalitis, uveitis, anterior uveitis, acute anterior uveitis, granulomatous uveitis, non-granulomatous uveitis, phacoantigenic uveitis,Posterior uveitis, autoimmune uveitis, glomerulonephritis (GN), idiopathic membranous GN or idiopathic membranous nephropathy, membrano proliferative or membranous proliferative GN (MPGN), rapidly progressive GN, allergic conditions, autoimmune myocarditis, leukocyte adhesion deficiency, systemic lupus erythematosus (SLE), systemic lupus erythematodes, e.g. cutaneous SLE, subacute cutaneous lupus erythematosus, neonatal lupus syndrome (NLE), generalized lupus erythematosus disseminatas), lupus (including nephritis, encephalitis, pediatric, non-renal, extrarenal, discoid, alopecia), juvenile-onset (Type I) diabetes mellitus including insulin-dependent diabetes mellitus of childhood (IDDM), adult-onset diabetes mellitus (Type II diabetes), autoimmune diabetes, idiopathic diabetes insipidus, immune responses associated with acute and delayed hypersensitivity mediated by cytokines and T lymphocytes, tuberculosis, sarcoidosis, granulomatosis, lymphomatoid granulomatosis, Wegener's granulomatosis, agranulocytosis, vasculitis, large vasculitis, rheumatoid polyposis Myalgia, giant cell (Takayasu) arteritis, medium vasculitis, Kawasaki disease, polyarteritis nodosa, microscopic polyarteritis, CNS vasculitis, necrotizing, cutaneous, hypersensitivity vasculitis, systemic necrotizing vasculitis, and vasculitis including temporal arteritis, ANCA-associated vasculitis, e.g., Churg-Strauss vasculitis or syndrome (CSS), aplastic anemia, autoimmune aplastic anemia, Coombs positive anemia, Diamond-Blackfan anemia, hemolytic anemia, or immune hemolytic anemia including autoimmune hemolytic anemia (AIHA), pernicious anemia anemia (perniciosa), Addison's disease, pure red cell anemia or aplasia (PRCA), factor VIII deficiency, hemophilia A, autoimmune neutropenia, pancytopenia, leukopenia, diseases involving leukocyte emigration, CNS inflammatory disorders, multiple organ injury syndromes, such as those secondary to sepsis, trauma, or hemorrhage, antigen-antibody complex-mediated diseases, antiglomerular basement membrane disease, antiphospholipid syndrome, allergic neuritis,Bechet's or Behcet's disease, Castleman's syndrome, Goodpasture's syndrome, Raynaud's syndrome, Sjogren's syndrome, Stevens-Johnson syndrome, pemphigoid, e.g. bullous pemphigoid and cutaneous pemphigoid, pemphigus, optionally pemphigus vulgaris, pemphigus foliaceus, mucous membrane pemphigoid, pemphigus erythematous, autoimmune polyendocrinopathy, Reiter's disease or syndrome, immune complex nephritis, antibody-mediated nephritis, neuromyelitis optica, polyneuropathy, Chronic neuropathies, IgM polyneuropathy, IgM-mediated neuropathy, thrombocytopenia, thrombotic thrombocytopenic purpura (TTP), idiopathic thrombocytopenic purpura (ITP), autoimmune orchitis and oophoritis, primary hypothyroidism, hypoparathyroidism, autoimmune thyroiditis, Hashimoto's disease, chronic thyroiditis (Hashimoto's thyroiditis), subacute thyroiditis, autoimmune thyroid disease, idiopathic hypothyroidism, Graves' disease, polyglandular syndromes, e.g. autoimmune polyglandular syndrome (or polyendocrine syndrome), paraneoplastic syndromes including neurological paraneoplastic syndromes, e.g., Lambert-Eaton myasthenic syndrome or Eaton-Lambert syndrome, stiff-man or stiff-person syndrome, encephalomyelitis, allergic encephalomyelitis, experimental allergic encephalomyelitis (EAE), myasthenia gravis, thymoma-associated myasthenia gravis, cerebellar degeneration, neuromyotonia, opsoclonus or opsoclonus-myoclonus syndrome (OMS), and sensory Neuropathies, multifocal motor neuropathy, Sheehan's syndrome, autoimmune hepatitis, chronic hepatitis, lupoid hepatitis, giant cell hepatitis, chronic active hepatitis or autoimmune chronic active hepatitis, lymphocytic interstitial pneumonia, bronchiolitis obliterans (non-transplant) and NSIP, Guillain-Barre syndrome, Berger's disease (IgA nephropathy), idiopathic IgA nephropathy, linear IgA dermatosis, primary biliary cirrhosis, pneumonic cirrhosis, autoimmune enteropathy syndrome, celiac disease disease), celiac disease, celiac sprue (gluten enteropathy), refractory sprue, idiopathic sprue, cryoglobulinemia, amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease), coronary artery disease, autoimmune ear diseases, such as autoimmune inner ear disease (AGED), autoimmune hearing loss, opsoclonus-myoclonus syndrome (OMS), polychondritis,and / or other conditions, such as refractory or relapsing polychondritis, pulmonary alveolar proteinosis, amyloidosis, scleritis, non-cancerous lymphocytosis, monoclonal B-cell lymphocytosis, optionally primary lymphocytosis including benign monoclonal gammopathy or monoclonal gammopathy of undetermined significance (MGUS), peripheral neuropathy, paraneoplastic syndromes, channelopathies, such as epilepsy, migraine, arrhythmias, myopathy, hearing loss, blindness, periodic paralysis, and channelopathies of the CNS, autism, inflammatory myopathy, focal segmental glomerulosclerosis (FSGS), endocrine ophthalmopathy, uveitis retinitis, chorioretinitis, autoimmune hepatopathy, fibromyalgia, multiple endocrine deficiencies, Schmidt's syndrome, adrenal inflammation, gastrotrophy, presenile dementia, degenerative diseases, and the like. Myelopathy, such as autoimmune demyelinating diseases, diabetic nephropathy, Dressler's syndrome, alopecia areata, Crest syndrome (calcinosis, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasia), male and female autoimmune infertility, mixed connective tissue disease, Chagas' disease, rheumatic fever, recurrent pregnancy loss, farmer's lung, erythema multiforme, postpericardiotomy syndrome, Cushing's syndrome, bird breeder's disease, allergic granulomatous vasculitis, benign lymphocytic vasculitis, Alport's syndrome, alveolitis, such as allergic alveolitis and fibrosing alveolitis, interstitial lung disease, transfusion reactions, leprosy, malaria, leishmaniasis, kypanosomiasis, schistosomiasis, ascariasis, aspergillosis, Sumpter's syndrome, syndrome), Kaplan's syndrome, dengue fever, endocarditis, endomyocardial fibrosis, diffuse interstitial pulmonary fibrosis, interstitial pulmonary fibrosis, idiopathic pulmonary fibrosis, cystic fibrosis, endophthalmitis, elevate pulmonary syndrome, diutinum erythema, erythroblastosis fetalis, eosinophilic fasciitis, Charmant's syndrome, Felty's syndrome, filariasis, cyclitis, such as chronic cyclitis, heterochromatic cyclitis, iridocyclitis, or Fuchs' cyclitis, Henoch-Schönlein purpura, human immunodeficiency virus (HIV) infection, echovirus infection, cardiomyopathy, Alzheimer's disease, parvovirus infection, rubella virus infection, post-vaccination syndrome, congenital rubella infection, Epstein-Barr virus infection, mumps, Evans' syndrome, autoimmune gonadal dysfunction, Sydenham's chorea, post-streptococcal nephritis,Thromboangitis ubiterans, thyrotoxicosis, spinal cord fistula, choroiditis, giant cell polymyalgia, endocrine ophthalmopathy, chronic hypersensitivity pneumonitis, keratoconjunctivitis sicca, epidemic keratoconjunctivitis, idiopathic nephritic syndrome, minimal change nephropathy, benign familial and ischemia-reperfusion injury, retinal autoimmunity, arthritis, bronchitis, chronic obstructive airway disease, silicosis, aphthous stomatitis, arteriosclerotic disorders, aspermiogenesis, autoimmune hemolysis, Beck's disease, cryoglobulinemia, Dupuytren's contracture, endophthalmia phacoanaphylactica), allergic enteritis, leprous erythema nodosum, idiopathic facial paralysis, chronic fatigue syndrome, rheumatic fever (febris rheumatica), Hammann-Rich disease, sensorineural deafness, paroxysmal hemoglobinuria (haemoglobinuria paroxysmatica), hypogonadism, regional ileitis (ileitis regionalis), leukopenia, infectious mononucleosis (mononucleosis infectioussa), transverse myelitis, primary idiopathic myxedema, nephrosis, sympathetic ophthalmia (ophthalmia symphatica), granulomatous orchitis, pancreatitis (e.g. chronic pancreatitis), polyradiculitis acuta, pyoderma gangrenosum, Kervan thyroiditis, acquired splenic atrophy, infertility due to antispermatozoan antobody, non-malignant thymoma, vitiligo, SCID and Epstein-Barr virus related diseases, acquired immune deficiency syndrome (AIDS), parasitic diseases such as leishmania, toxic shock syndrome, food poisoning, conditions involving T cell infiltration, leukocyte adhesion deficiency, immune responses associated with cytokines and T lymphocyte mediated acute and delayed type hypersensitivity, diseases involving leukocyte emigration, multiple organ injury syndrome, antigen-antibody Complex-mediated diseases, anti-glomerular basement membrane disease, allergic neuritis, autoimmune polyendocrinopathy, oophoritis, primary myxedema, autoimmune atrophic gastritis, sympathetic ophthalmia, rheumatic diseases, mixed connective tissue disease, nephrotic syndrome, insulitis, polyglandular insufficiency, peripheral neuropathy, autoimmune polyglandular syndrome type I, adult-onset idiopathic hypoparathyroidism (AOIH), alopecia totalis, dilated cardiomyopathy, epidermolysis bullosa acquisita (EBA),Hemochromatosis, myocarditis, nephrotic syndrome, primary sclerosing cholangitis, suppurative or non-suppurative sinusitis, acute or chronic sinusitis, ethmoid, frontal, maxillary, or sphenoid sinusitis, eosinophil-related diseases such as eosinophilia, pulmonary infiltrative eosinophilia, eosinophilic myalgia syndrome, Löffler's syndrome, chronic eosinophilic pneumonia, tropical pulmonary eosinophilia, bronchopulmonary aspergillosis, aspergilloma, or eosinophil-containing granuloma, anaphylaxis, seronegative spondyloarthritis, polyglandular autoimmune disease, sclerosing cholangitis, scleritis, episcleritis, chronic mucocutaneous candidiasis, Bruton's syndrome, transient hypogammaglobulinemia of infancy, Wiskott-Aldrich syndrome, ataxia-telangiectasia, autoimmune diseases associated with collagen diseases, rheumatism, neurological diseases, ischemia-reperfusion injury, hyporesponsiveness of blood pressure, vascular dysfunction, antgiectasis, tissue injury, cardiovascular ischemia, and pain sensation hypersensitivity, cerebral ischemia, and angiogenesis, allergic hypersensitivity disorders, glomerulonephritides, reperfusion injury, myocardial or other tissue reperfusion injury, skin diseases with acute inflammatory components, acute purulent meningitis, or other central nervous system inflammatory disorders, ocular and orbital inflammatory disorders, granulocyte transfusion-associated syndrome, cytokine-induced toxicity, acute intense inflammation, chronic refractory inflammation, pyelitis, pneumonocirrhosis, diabetic retinopathy, diabetic aortopathy, endarterial hyperplasia, peptic ulcer, valvulitis, and endometriosis, The method of claim 15.
17. The patient is suffering from systemic lupus erythematosus or antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV). The method of claim 15.
18. The patient is suffering from a viral-induced inflammation, in particular COVID-19. The method of claim 15.
19. A pharmaceutical composition comprising the antibody of claim 1.
Citation Information
Patent Citations
Remedies for pemphigus containing anti fas ligand antibodies
US20110038867A1
Polypeptides and uses thereof for reducing CD95-mediated cell motility
WO2015158810A1
Anti-CD95l antibody
WO2017051002A1
MONOCLONAL ANTIBODY REACTING SPECIFICALLY WITH Fas LIGAND AND PROCESS FOR PRODUCING THE SAME
WO1996029350A1
